AMRX
Price
$9.62
Change
+$0.07 (+0.73%)
Updated
Sep 5 closing price
Capitalization
3.02B
62 days until earnings call
DVAX
Price
$10.06
Change
+$0.08 (+0.80%)
Updated
Sep 5 closing price
Capitalization
1.18B
54 days until earnings call
Interact to see
Advertisement

AMRX vs DVAX

Header iconAMRX vs DVAX Comparison
Open Charts AMRX vs DVAXBanner chart's image
Amneal Pharmaceuticals
Price$9.62
Change+$0.07 (+0.73%)
Volume$1.27M
Capitalization3.02B
Dynavax Technologies
Price$10.06
Change+$0.08 (+0.80%)
Volume$1.42M
Capitalization1.18B
AMRX vs DVAX Comparison Chart in %
Loading...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. DVAX commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Buy and DVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (AMRX: $9.62 vs. DVAX: $10.06)
Brand notoriety: AMRX and DVAX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 86% vs. DVAX: 89%
Market capitalization -- AMRX: $3.02B vs. DVAX: $1.18B
AMRX [@Pharmaceuticals: Generic] is valued at $3.02B. DVAX’s [@Pharmaceuticals: Generic] market capitalization is $1.18B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • DVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, AMRX is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 5 TA indicator(s) are bullish while DVAX’s TA Score has 4 bullish TA indicator(s).

  • AMRX’s TA Score: 5 bullish, 4 bearish.
  • DVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AMRX is a better buy in the short-term than DVAX.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а +0.63% price change this week, while DVAX (@Pharmaceuticals: Generic) price change was -0.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

AMRX is expected to report earnings on Nov 07, 2025.

DVAX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($3.02B) has a higher market cap than DVAX($1.18B). AMRX has higher P/E ratio than DVAX: AMRX (962.00) vs DVAX (54.60). AMRX YTD gains are higher at: 21.465 vs. DVAX (-21.222). AMRX has higher annual earnings (EBITDA): 584M vs. DVAX (-34.26M). DVAX has more cash in the bank: 614M vs. AMRX (71.5M). DVAX has less debt than AMRX: DVAX (285M) vs AMRX (2.58B). AMRX has higher revenues than DVAX: AMRX (2.85B) vs DVAX (316M).
AMRXDVAXAMRX / DVAX
Capitalization3.02B1.18B256%
EBITDA584M-34.26M-1,705%
Gain YTD21.465-21.222-101%
P/E Ratio962.0054.601,762%
Revenue2.85B316M903%
Total Cash71.5M614M12%
Total Debt2.58B285M906%
FUNDAMENTALS RATINGS
AMRX vs DVAX: Fundamental Ratings
AMRX
DVAX
OUTLOOK RATING
1..100
2658
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
5085
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
4382
P/E GROWTH RATING
1..100
3197
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (69) in the Biotechnology industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that DVAX’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (50) in the Pharmaceuticals Major industry is somewhat better than the same rating for DVAX (85) in the Biotechnology industry. This means that AMRX’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's SMR Rating (95) in the Biotechnology industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that DVAX’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Price Growth Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for DVAX (82) in the Biotechnology industry. This means that AMRX’s stock grew somewhat faster than DVAX’s over the last 12 months.

AMRX's P/E Growth Rating (31) in the Pharmaceuticals Major industry is significantly better than the same rating for DVAX (97) in the Biotechnology industry. This means that AMRX’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXDVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 4 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 25 days ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 5 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APHDX23.23N/A
N/A
Artisan Global Discovery Institutional
PJERX15.29N/A
N/A
PGIM Jennison Global Equity Income R
PGKAX28.99N/A
N/A
PGIM Jennison Technology A
PLGIX18.14-0.04
-0.22%
Principal LargeCap Growth I Instl
DGAGX40.51-0.19
-0.47%
BNY Mellon Appreciation Investor

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with PAHC. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+0.73%
PAHC - AMRX
46%
Loosely correlated
+0.97%
VTRS - AMRX
43%
Loosely correlated
+1.65%
TEVA - AMRX
40%
Loosely correlated
+2.54%
COLL - AMRX
39%
Loosely correlated
-2.32%
ALKS - AMRX
38%
Loosely correlated
+3.53%
More

DVAX and

Correlation & Price change

A.I.dvisor tells us that DVAX and BCRX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DVAX and BCRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.80%
BCRX - DVAX
32%
Poorly correlated
N/A
AMRX - DVAX
32%
Poorly correlated
+0.73%
ESPR - DVAX
32%
Poorly correlated
+5.93%
ALKS - DVAX
32%
Poorly correlated
+3.53%
SUPN - DVAX
29%
Poorly correlated
+1.25%
More